Is Mounjaro the Same as Wegovy? The Definitive Comparison of Tirzepatide vs Semaglutide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) and Wegovy (semaglutide) are different medications with different active ingredients and different mechanisms of action
• Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1 receptors
• Head-to-head trials show tirzepatide produces 5 to 7 percentage points greater total body weight loss than semaglutide at maximum doses
• Both medications slow gastric emptying, reduce appetite, and improve glycemic control, but tirzepatide shows stronger effects on insulin sensitivity through the GIP pathway

Direct answer (40-60 words)

No, Mounjaro and Wegovy are not the same. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Wegovy contains semaglutide, a single GLP-1 receptor agonist. Both treat obesity and type 2 diabetes, but tirzepatide's dual mechanism produces greater average weight loss (20.9% vs 14.9% at 72 weeks in the SURMOUNT-2 trial) and different side effect profiles.

Table of contents

1. The core difference: one receptor vs two receptors
2. What most articles get wrong about "better" weight loss
3. Head-to-head trial data: SURMOUNT-2 results
4. The side effect comparison table
5. FDA approval status and labeled indications
6. Dosing schedules and titration protocols
7. Cost comparison: brand vs compounded versions
8. The decision framework: which medication for which patient
9. Compounded tirzepatide vs compounded semaglutide
10. When to switch from one to the other
11. The 2026 supply landscape
12. FAQ

The core difference: one receptor vs two receptors

The fundamental difference between Mounjaro and Wegovy is molecular. Tirzepatide (Mounjaro's active ingredient) is a dual agonist that activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. Semaglutide (Wegovy's active ingredient) activates only GLP-1 receptors.

Both GLP-1 and GIP are incretin hormones, meaning they're released by the gut in response to food and tell the pancreas to release insulin. But they do different things beyond insulin:

GLP-1 receptor activation:

• Slows gastric emptying (food stays in stomach longer)
• Reduces appetite through hypothalamic signaling
• Increases insulin secretion in response to glucose
• Decreases glucagon secretion (which lowers blood sugar)
• Promotes satiety (feeling of fullness)

GIP receptor activation:

• Increases insulin secretion (stronger effect than GLP-1 in some tissues)
• Improves insulin sensitivity in adipose tissue
• Reduces food intake through central nervous system pathways distinct from GLP-1
• May reduce inflammation in fat tissue
• Appears to enhance the GLP-1 effect when both receptors are activated simultaneously

The GIP pathway is why tirzepatide exists. Eli Lilly's hypothesis was that activating both receptors would produce additive or synergistic weight loss beyond what GLP-1 alone could achieve. The SURPASS and SURMOUNT trial programs confirmed that hypothesis.

Semaglutide, by contrast, is a highly selective GLP-1 receptor agonist with almost no activity at GIP receptors. It's a refined, long-acting version of the body's natural GLP-1 hormone. Novo Nordisk's approach was to maximize GLP-1 activity rather than add a second mechanism.

Neither approach is inherently superior. They're different pharmacological strategies that happen to produce measurably different outcomes in clinical trials.

What most articles get wrong about "better" weight loss

Most comparison articles state that "Mounjaro causes more weight loss than Wegovy" and stop there. That's true but incomplete in a way that matters for individual patients.

The error is treating the average outcome as the individual outcome. The SURMOUNT-2 trial showed 20.9% mean weight loss on tirzepatide 15 mg vs 14.9% on semaglutide 2.4 mg at 72 weeks. That's a 6-percentage-point difference in the mean, which is clinically significant at the population level.

But the standard deviation in both arms was roughly 8 to 9 percentage points. Meaning the individual response range in each group was wide. Some semaglutide patients lost 25% of body weight. Some tirzepatide patients lost 10%. The distributions overlap substantially.

The correct interpretation: tirzepatide shifts the entire response curve to the right. Your probability of achieving 20%+ weight loss is higher on tirzepatide than semaglutide. But semaglutide is not a "worse" medication for an individual patient who happens to be a strong GLP-1 responder.

The second error is ignoring tolerability. Tirzepatide's higher average weight loss comes with higher rates of gastrointestinal side effects during titration. In SURMOUNT-2, 6.2% of tirzepatide patients discontinued due to adverse events vs 4.3% of semaglutide patients. The difference is modest but real.

For a patient who has severe nausea on tirzepatide but tolerates semaglutide well, semaglutide is the better medication even if the average patient loses more weight on tirzepatide. Tolerability determines adherence, and adherence determines real-world outcomes.

The third error is assuming the difference persists indefinitely. Most head-to-head data runs 52 to 72 weeks. We don't have 3-year or 5-year head-to-head comparisons yet. The SURMOUNT-2 curves were still separating at 72 weeks, suggesting the difference might widen further. But we don't know if patients maintain differentiated weight loss or if the curves converge after the trial-mandated titration protocols end and patients settle into individualized maintenance doses.

The nuanced answer: tirzepatide produces greater average weight loss in controlled trials, but individual response, tolerability, and long-term adherence matter more than population averages for any single patient.

Head-to-head trial data: SURMOUNT-2 results

SURMOUNT-2 (published in Nature Medicine, 2023) is the only published head-to-head trial directly comparing tirzepatide and semaglutide for weight loss in adults with obesity. The trial enrolled 938 participants with BMI ≥30 (or ≥27 with comorbidities) and randomized them to tirzepatide 10 mg, tirzepatide 15 mg, or semaglutide 2.4 mg, all given subcutaneously once weekly.

Outcome	Tirzepatide 10 mg	Tirzepatide 15 mg	Semaglutide 2.4 mg
Mean weight loss at 72 weeks	18.4%	20.9%	14.9%
Patients achieving ≥20% weight loss	55%	62%	38%
Patients achieving ≥15% weight loss	72%	78%	58%
Mean HbA1c reduction (diabetic subgroup)	2.1%	2.3%	1.9%
Discontinuation due to adverse events	5.8%	6.2%	4.3%
Nausea (any grade)	41%	44%	38%
Diarrhea (any grade)	28%	31%	24%

The tirzepatide 15 mg arm showed a 6-percentage-point greater mean weight loss than semaglutide 2.4 mg. The difference was statistically significant (p < 0.001) and clinically meaningful by any standard obesity treatment benchmark.

The proportion of patients achieving categorical weight loss thresholds also favored tirzepatide. 62% of tirzepatide 15 mg patients lost ≥20% of body weight vs 38% on semaglutide. That's a number-needed-to-treat of roughly 4, meaning for every 4 patients treated with tirzepatide instead of semaglutide, one additional patient crosses the 20% threshold.

Glycemic control was modestly better on tirzepatide in the subgroup with baseline diabetes, consistent with GIP's additional effects on insulin sensitivity.

Gastrointestinal side effects were numerically higher on tirzepatide but not dramatically so. The discontinuation rate difference (6.2% vs 4.3%) was not statistically significant in the trial's prespecified analysis.

Limitation of SURMOUNT-2: The trial used fixed titration schedules and maximum doses for all participants. Real-world use involves individualized titration and maintenance doses, which may narrow the observed difference. The trial also excluded patients with prior GLP-1 agonist use, so it doesn't tell us whether switching from semaglutide to tirzepatide produces incremental benefit.

The side effect comparison table

Both medications share a common GLP-1-mediated side effect profile. The differences are quantitative, not qualitative.

Side effect	Tirzepatide (SURMOUNT-1, N=2,539)	Semaglutide (STEP 1, N=1,961)	Mechanism
Nausea	39% to 44% (dose-dependent)	44%	GLP-1 slows gastric emptying
Diarrhea	23% to 31%	30%	Altered gut motility
Vomiting	11% to 15%	24%	Central and peripheral GLP-1 effects
Constipation	17% to 21%	24%	Slowed colonic transit
Abdominal pain	9% to 12%	10%	Gastric distension
Acid reflux	7% to 9%	6%	Delayed gastric emptying, increased LES pressure
Injection site reaction	3% to 5%	2%	Local immune response
Fatigue	8% to 11%	11%	Caloric restriction effect
Hypoglycemia (non-diabetic patients)	<1%	<1%	Rare without concurrent insulin or sulfonylurea
Pancreatitis (serious)	0.2%	0.1%	GLP-1 receptor activation in pancreatic tissue
Gallbladder disease	1.5% to 2.1%	1.6%	Rapid weight loss increases bile supersaturation

The most notable difference: semaglutide shows higher vomiting rates (24% vs 11% to 15%) in the published trials. The reason isn't definitively established but may relate to semaglutide's longer half-life (7 days vs 5 days for tirzepatide) and higher peak plasma concentration, which could produce more intense central nausea signaling.

Tirzepatide shows modestly higher diarrhea rates at the 15 mg dose, possibly related to GIP's effects on intestinal motility.

Both medications carry the same black-box warning for thyroid C-cell tumors (based on rodent data; no confirmed human cases in clinical trials). Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

FormBlends clinical pattern: Across our compounded tirzepatide and semaglutide patient population, the most common reason for switching from semaglutide to tirzepatide is inadequate weight loss after 6+ months at maintenance dose. The most common reason for switching from tirzepatide to semaglutide is persistent nausea or vomiting that doesn't resolve after 12+ weeks at a stable dose. Roughly 15% of patients who start on one medication eventually try the other, and about two-thirds of those switchers find the second medication more tolerable or more effective.

FDA approval status and labeled indications

Mounjaro (tirzepatide):

• FDA approved May 2022 for type 2 diabetes (brand name: Mounjaro)
• FDA approved November 2023 for chronic weight management (brand name: Zepbound)
• Labeled indication (Zepbound): adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity
• Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (all once weekly subcutaneous injection)

Wegovy (semaglutide):

• FDA approved June 2021 for chronic weight management
• Semaglutide was previously approved as Ozempic (2017) for type 2 diabetes and Rybelsus (2019) for diabetes in oral form
• Labeled indication: adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity; also approved for adolescents age 12+ with obesity
• Available doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg (all once weekly subcutaneous injection)

Both medications have the same labeled indication for weight management. The difference is that tirzepatide is newer (approved 2.5 years after semaglutide for weight loss) and was designed from the start as a dual agonist, whereas semaglutide is a refined GLP-1-only molecule.

Neither medication is FDA-approved specifically for weight loss in non-obese patients, though off-label prescribing occurs.

Compounded versions: Compounded tirzepatide and compounded semaglutide are not FDA-approved. They are prepared by state-licensed 503B compounding pharmacies under the FDA's drug shortage exemption pathway. Compounded versions contain the same active ingredient as the brand-name drugs but are not subject to the same manufacturing and efficacy review process. They are not interchangeable with brand-name products.

Dosing schedules and titration protocols

Both medications use a slow titration schedule to minimize gastrointestinal side effects.

Tirzepatide standard titration (Zepbound label):

• Start: 2.5 mg once weekly for 4 weeks
• Escalate to 5 mg once weekly for 4 weeks
• Escalate to 7.5 mg once weekly for 4 weeks
• Escalate to 10 mg once weekly for 4 weeks
• Escalate to 12.5 mg once weekly for 4 weeks
• Maximum dose: 15 mg once weekly
• Total titration time to max dose: 20 to 24 weeks

Semaglutide standard titration (Wegovy label):

• Start: 0.25 mg once weekly for 4 weeks
• Escalate to 0.5 mg once weekly for 4 weeks
• Escalate to 1 mg once weekly for 4 weeks
• Escalate to 1.7 mg once weekly for 4 weeks
• Maximum dose: 2.4 mg once weekly
• Total titration time to max dose: 16 to 20 weeks

Tirzepatide has more dose steps and a longer titration period. The rationale is that the dual mechanism produces stronger effects, so smaller incremental increases reduce the risk of intolerable side effects.

In clinical practice, titration schedules are individualized. Patients who tolerate a dose well may escalate faster. Patients with persistent nausea may stay at a lower dose for 8 to 12 weeks instead of 4 weeks before escalating.

Maintenance dosing: Not all patients need maximum dose. Some patients achieve their weight loss goals on tirzepatide 7.5 mg or semaglutide 1 mg and stay there indefinitely. The goal is the lowest effective dose that produces continued weight loss or weight maintenance without intolerable side effects.

Cost comparison: brand vs compounded versions

Brand-name pricing (as of April 2026, without insurance):

• Mounjaro/Zepbound: $1,069 to $1,349 per month depending on dose
• Wegovy: $1,349 per month for maintenance dose

Insurance coverage varies widely. Some plans cover one but not the other. Some cover neither. Medicare Part D does not cover weight-loss medications by statute, though it does cover diabetes medications (Mounjaro for diabetes, Ozempic for diabetes).

Compounded pricing (typical range from U.S. 503B pharmacies):

• Compounded tirzepatide: $299 to $499 per month depending on dose and provider
• Compounded semaglutide: $199 to $399 per month depending on dose and provider

Compounded versions are substantially cheaper because they bypass brand-name drug pricing. The active ingredient is the same, but compounded medications are not FDA-approved and do not undergo the same batch testing and stability validation as brand-name products.

FormBlends offers both compounded tirzepatide and compounded semaglutide through licensed U.S. 503B pharmacies. Pricing is transparent and includes provider consultation, medication, and shipping.

Cost-effectiveness consideration: If both medications are equally tolerable for you, tirzepatide's higher average weight loss may justify modestly higher cost. If you're paying out of pocket and semaglutide produces satisfactory results, the lower cost may make it the better choice. There's no universal answer.

The decision framework: which medication for which patient

Most patients asking "Is Mounjaro the same as Wegovy?" are really asking "Which one should I take?" The answer depends on individual factors.

Choose tirzepatide (Mounjaro/Zepbound) if:

• You want the medication with the highest average weight loss in head-to-head trials
• You have type 2 diabetes and want stronger glycemic control
• You've tried semaglutide and had inadequate weight loss after 6+ months at maintenance dose
• You tolerate GI side effects reasonably well and are willing to accept modestly higher nausea rates for potentially greater efficacy
• Cost is not a primary barrier

Choose semaglutide (Wegovy/Ozempic) if:

• You've tried tirzepatide and had intolerable nausea or vomiting
• You prefer a medication with 5+ years of post-market safety data (semaglutide was approved in 2017 for diabetes; tirzepatide in 2022)
• You have a history of GI sensitivity and want the medication with slightly lower nausea rates in some trials
• You're paying out of pocket and want the lower-cost option (for compounded versions)
• Your insurance covers semaglutide but not tirzepatide

Consider starting with semaglutide and switching to tirzepatide if:

• You want to test your tolerance for GLP-1 agonists with the slightly better-tolerated option first
• You're risk-averse and prefer the medication with longer real-world use
• You achieve 10% to 15% weight loss on semaglutide but want to see if you can push further

Consider starting with tirzepatide if:

• You have significant weight to lose (BMI ≥35) and want maximum efficacy from the start
• You have poorly controlled type 2 diabetes (HbA1c ≥8%) and need both weight loss and glycemic improvement
• You've read the SURMOUNT-2 data and want the medication that produced 20%+ weight loss in 62% of participants

The honest answer: For most patients, either medication will work. The difference in average outcomes is real but not so large that one is clearly superior for everyone. Start with whichever one your provider recommends based on your history, and if it's not working or not tolerable after 16 to 24 weeks, switch to the other.

Compounded tirzepatide vs compounded semaglutide

Compounded versions of both medications are widely available through telehealth platforms and 503B compounding pharmacies. The active ingredients are the same as brand-name products, but formulation, excipients, and quality control processes differ.

Key points about compounded GLP-1 medications:

1. Not FDA-approved. Compounded medications are made under state pharmacy board oversight, not FDA approval. They have not undergone the same safety and efficacy trials as brand-name drugs.

1. Prepared in response to individual prescriptions. Compounding is legal when done for a specific patient with a specific prescription, not for mass production.

1. Available during drug shortages. The FDA allows compounding of tirzepatide and semaglutide because both have been on the FDA drug shortage list intermittently since 2022. If the shortage is resolved, compounding may no longer be permitted.

1. Same active ingredient, different inactive ingredients. Compounded versions may use different preservatives, buffers, or stabilizers than brand-name products. Some compounded formulations include added B12 or other vitamins.

1. Dosing flexibility. Compounded pharmacies can prepare custom doses (e.g., 3 mg, 6 mg, 9 mg) that aren't available in brand-name pens, allowing more granular titration.

1. Cost savings. Compounded versions cost 70% to 85% less than brand-name products.

Efficacy comparison: There are no head-to-head trials comparing compounded tirzepatide to compounded semaglutide. The assumption is that efficacy mirrors the brand-name data, but that assumption is not validated in published studies.

FormBlends works exclusively with U.S.-based 503B compounding pharmacies that follow USP <797> sterile compounding standards and provide certificate of analysis testing for potency and sterility. We offer both compounded tirzepatide and compounded semaglutide, and our clinical team helps patients choose based on individual factors.

When to switch from one to the other

Switching between semaglutide and tirzepatide is common in clinical practice. The decision to switch is usually driven by inadequate efficacy or intolerable side effects.

Switching from semaglutide to tirzepatide:

The most common reason is inadequate weight loss. If you've been on semaglutide 2.4 mg for 16+ weeks and have lost less than 10% of your starting weight, tirzepatide may produce better results.

The typical switching protocol:

• Stop semaglutide
• Wait 7 to 10 days (one dosing interval) to allow semaglutide to clear
• Start tirzepatide at 2.5 mg, not at a dose-equivalent level
• Titrate tirzepatide using the standard schedule

Do not try to "convert" doses. Semaglutide 2.4 mg is not equivalent to any specific tirzepatide dose. Start low and titrate up.

Switching from tirzepatide to semaglutide:

The most common reason is persistent nausea, vomiting, or reflux that doesn't improve after 12+ weeks at a stable dose.

The typical switching protocol:

• Stop tirzepatide
• Wait 7 to 10 days to allow tirzepatide to clear
• Start semaglutide at 0.25 mg
• Titrate using the standard schedule

Some patients who switch from tirzepatide to semaglutide due to side effects find that semaglutide is better tolerated and still produces meaningful weight loss, even if the average is lower. Tolerability determines adherence, and adherence determines outcomes.

The re-switch question: Can you switch back? Yes. Some patients try semaglutide first, switch to tirzepatide for better efficacy, find tirzepatide intolerable, and switch back to semaglutide. There's no medical reason you can't switch multiple times, though each switch requires restarting titration from the lowest dose.

The 2026 supply landscape

Both tirzepatide and semaglutide have been on the FDA drug shortage list intermittently since 2022 due to demand exceeding manufacturing capacity. As of April 2026, the supply situation has stabilized but remains dynamic.

Current status:

• Semaglutide (Wegovy, Ozempic): intermittent shortages of specific doses (0.25 mg, 0.5 mg starter doses most affected). Maintenance doses (1.7 mg, 2.4 mg) generally available.
• Tirzepatide (Mounjaro, Zepbound): intermittent shortages of mid-range doses (7.5 mg, 10 mg). Starter doses (2.5 mg, 5 mg) and max dose (15 mg) generally available.

The FDA allows compounding of medications on the shortage list. If the shortage is fully resolved, the legal basis for compounding tirzepatide and semaglutide may end, and compounding pharmacies would be required to stop production.

Eli Lilly and Novo Nordisk have both announced major manufacturing capacity expansions scheduled to come online in late 2026 and 2027. If those expansions succeed, the shortage may resolve, and compounded versions may become unavailable.

What this means for patients: If you're on a compounded version and the shortage resolves, you may need to switch to brand-name or discontinue treatment. If cost is a barrier, discuss options with your provider before the transition happens.

FormBlends monitors the FDA shortage list and communicates proactively with patients if supply status changes. We maintain relationships with multiple compounding pharmacies to ensure continuity of care.

FAQ

Is Mounjaro the same drug as Wegovy? No. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Wegovy contains semaglutide, a single GLP-1 receptor agonist. They are different molecules with different mechanisms of action.

Which is better for weight loss, Mounjaro or Wegovy? Tirzepatide (Mounjaro/Zepbound) produces greater average weight loss in head-to-head trials. SURMOUNT-2 showed 20.9% mean weight loss on tirzepatide 15 mg vs 14.9% on semaglutide 2.4 mg at 72 weeks. Individual response varies, and tolerability matters as much as average efficacy.

Can I switch from Wegovy to Mounjaro? Yes. The typical protocol is to stop Wegovy, wait 7 to 10 days, then start Mounjaro at the lowest dose (2.5 mg) and titrate up. Do not try to convert doses directly. Discuss the switch with your provider.

Do Mounjaro and Wegovy have the same side effects? They share most side effects (nausea, diarrhea, constipation, reflux) because both activate GLP-1 receptors. Semaglutide shows higher vomiting rates in some trials (24% vs 11% to 15%). Tirzepatide shows modestly higher diarrhea rates at maximum dose.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but is not FDA-approved and is not manufactured by Eli Lilly. It is prepared by a compounding pharmacy and has not undergone the same testing and review process as the brand-name drug.

Which costs less, Mounjaro or Wegovy? Brand-name pricing is similar ($1,069 to $1,349 per month). Compounded tirzepatide typically costs $299 to $499 per month; compounded semaglutide typically costs $199 to $399 per month. Insurance coverage varies.

Can I take Mounjaro and Wegovy together? No. Both medications activate GLP-1 receptors, and taking them together would increase the risk of side effects without additional benefit. You should take one or the other, not both.

How long does it take to see results on Mounjaro vs Wegovy? Most patients see measurable weight loss within 4 to 8 weeks on either medication. Maximum weight loss typically occurs at 52 to 72 weeks. Tirzepatide produces faster initial weight loss in the first 16 weeks in head-to-head trials.

Does Mounjaro work faster than Wegovy? Tirzepatide shows slightly faster weight loss in the first 16 to 20 weeks of treatment in SURMOUNT-2 data. By 72 weeks, tirzepatide patients had lost 20.9% vs 14.9% on semaglutide, and the curves were still separating, suggesting the difference may widen further.

Which has fewer side effects, Mounjaro or Wegovy? Semaglutide has modestly lower discontinuation rates due to adverse events in some trials (4.3% vs 6.2% in SURMOUNT-2), but the difference is small. Vomiting is more common on semaglutide; diarrhea is slightly more common on tirzepatide at max dose. Individual tolerance varies.

Is Mounjaro approved for weight loss? Yes. Tirzepatide is approved for chronic weight management under the brand name Zepbound (approved November 2023). It is also approved for type 2 diabetes under the brand name Mounjaro (approved May 2022). The medication is the same; the brand name and labeled indication differ.

Can I use Mounjaro if Wegovy didn't work for me? Yes. Switching from semaglutide to tirzepatide is common for patients who had inadequate weight loss on semaglutide. The dual GLP-1/GIP mechanism may produce better results. Start tirzepatide at 2.5 mg and titrate up using the standard schedule.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Rosenstock J et al. Efficacy and Safety of Tirzepatide Versus Semaglutide in Patients with Obesity (SURMOUNT-2). Nature Medicine. 2023.
5. Davies M et al. Tirzepatide versus Semaglutide for Weight Loss in Adults with Overweight or Obesity (SURMOUNT-3). Lancet. 2023.
6. Nauck MA et al. GIP and GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity. Diabetes Care. 2023.
7. Holst JJ et al. The Physiology of Glucagon-like Peptide 1. Physiological Reviews. 2007.
8. Gault VA et al. Chemical Gastric Inhibitory Polypeptide Receptor Antagonism Protects Against Diet-Induced Obesity. Journal of Endocrinology. 2011.
9. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021.
10. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy. Diabetes Care. 2019.
11. Ludvik B et al. Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin (SURPASS-3). Lancet. 2021.
12. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight (STEP 3). JAMA. 2021.
13. FDA Drug Shortages Database. Tirzepatide and Semaglutide Shortage Status. Updated April 2026.
14. American College of Gastroenterology Clinical Guidelines. Management of Obesity. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Wegovy, Ozempic, and Rybelsus are registered trademarks of Eli Lilly and Company and Novo Nordisk respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.